Skip to content
AnalystLens

Insmed 8-K Report, Financial Results (May 9, 2024)

Reports
Earnings & Results·Other Events·Exhibits & Filings
Filing Date
Filed May 9, 2024
Period End
May 9, 2024
Security
INSM
In the record · 2016–202610-K1110-Q338-K134

INSM filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 134 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jan ’18Jan ’18
  2. Leadership change8-K · May ’20May ’20
  3. Material agreement8-K · Oct ’22Oct ’22
  4. Leadership change8-K · Oct ’26Oct ’26

01—Abstract

Summary

Summary of the 8-K filed May 9, 2024. Cited figures are marked; the original filing is the authoritative source.

Insmed Incorporated reported first-quarter 2024 total revenue of $75.5 milliona, up 16% from $65.2 million in the first quarter of 2023.

ARIKAYCE net sales were $56.3 millionb in the U.S., $14.9 million in Japan, and $4.3 million in Europe and rest of world. The net loss narrowed to $157.1 million, or $1.06 per share, from $159.8 million, or $1.17 per share, a year earlier. Cash and cash equivalents were $595.7 million at March 31, 2024.

The company reiterated its 2024 global ARIKAYCE revenue guidance of $340 million to $360 millionc. The filing's main news is TPIP data. In the Phase 2 PH-ILD study, 79.3% of TPIP patients reached the 640 microgram maximum dose by Week 5, versus 100.0% on placebo.

Clinical worsening occurred in 10.3%d of TPIP patients versus 50.0% of placebo patients (p=0.0164), and deaths occurred in 6.9% versus 20.0%. The study enrolled 39 participants in a 3:1 randomization, and the company said it interprets the results with appropriate caution given the study's small size. The 6-minute walk distance improvement of 30 meters vs. placebo came with a wide confidence interval of -49.0 to 171.0 and a p-value of 0.3484.

In the Phase 2 PAH study, blended blinded data from the first 40 patients showed a mean 19.9% reduction in pulmonary vascular resistance and a 43-meter mean improvement in 6-minute walk distance. The company also said topline data from the Phase 3 ASPEN trial of brensocatib in bronchiectasis remain on track for the latter part of the second quarter of 2024.

If ASPEN is successful and approval is obtained, Insmed anticipates a U.S. launch in mid-2025. Shareholders' deficit was $464.8 million at March 31, 2024, and total debt, including the current portion, was reported on the balance sheet.

02—Key points

Key Highlights

  1. Q1 2024 total revenue of $75.5 million, up 16% from $65.2 million in Q1 2023; U.S. ARIKAYCE sales were $56.3 million.
  2. Net loss narrowed to $157.1 million ($1.06 per share) from $159.8 million ($1.17 per share) a year earlier; R&D expense fell to $121.1 million from $127.9 million, while SG&A rose to $93.1 million from $79.9 million.
  3. TPIP Phase 2 PH-ILD topline: clinical worsening in 10.3% of TPIP patients vs. 50.0% of placebo (p=0.0164); study of 39 participants, which the company said requires cautious interpretation.
  4. TPIP PH-ILD safety: treatment discontinuation due to adverse events in 13.8% of TPIP vs. 30.0% of placebo patients; serious adverse events in 20.7% vs. 40.0%; cough related to study drug in 37.9% of TPIP patients, all mild.
  5. TPIP Phase 2 PAH blended blinded data (first 40 patients): 19.9% mean PVR reduction and 43-meter mean 6-minute walk distance improvement.
  6. Cash and cash equivalents of $595.7 million at March 31, 2024; 2024 ARIKAYCE revenue guidance of $340 million to $360 million reiterated.
  7. Brensocatib Phase 3 ASPEN topline data expected in the latter part of Q2 2024; a U.S. launch is anticipated in mid-2025 if successful and approved.

03—Questions

Frequently Asked Questions

  1. How did ARIKAYCE perform in the first quarter of 2024?

    ARIKAYCE global revenue grew 16% year over year to a total of $75.5 million in Q1 2024 across product revenues. U.S. net sales were $56.3 million, Japan $14.9 million, and Europe and rest of world $4.3 million. The company reiterated full-year 2024 global ARIKAYCE revenue guidance of $340 million to $360 million.

  2. What were the main TPIP results from the Phase 2 PH-ILD study?

    The company reported that 79.3% of TPIP patients reached the maximum 640 microgram dose by Week 5, compared with 100.0% on placebo. Clinical worsening occurred in 10.3% of TPIP patients versus 50.0% of placebo patients (p=0.0164), and deaths occurred in 6.9% versus 20.0%. The 6-minute walk improvement of 30 meters had a wide confidence interval, and the company said the small study requires cautious interpretation. The company plans to discuss Phase 3 design with regulators and expects to start a Phase 3 study in 2025.

  3. What did the blinded PAH data show?

    Based on the first 40 patients who completed 16 weeks of treatment, including active and placebo arms, the mean reduction in pulmonary vascular resistance from baseline was 19.9% and the mean improvement in 6-minute walk distance was 43 meters. The company noted that these are blended blinded data, that the efficacy analysis used data available as of April 1, 2024, and that final results may differ. Topline Phase 2 PAH results are expected in 2025.

  4. What is the financial position and near-term catalyst?

    Insmed reported a Q1 2024 net loss of $157.1 million and cash and cash equivalents of $595.7 million at March 31, 2024. Shareholders' deficit was $464.8 million at that date. The next key catalyst cited is Phase 3 ASPEN topline data for brensocatib in bronchiectasis, expected in the latter part of Q2 2024, with a U.S. launch anticipated in mid-2025 if successful.

04—Continue

← View all 8-K filings